INTRODUCTION: Malignant pleural mesothelioma is a disease primarily associated with exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are associated with a high tumor mutation burden, mesothelioma is not. We sought to resolve this discrepancy. METHODS: We used mate-pair (n = 22), RNA (n = 28), and T cell receptor sequencing along with in silico predictions and immunologic assays to understand how structural variants of chromosomes affect the transcriptome. RESULTS: We observed that inter- or intrachromosomal rearrangements were present in every specimen and were frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis. Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones. T cells responsive to these predicted neoantigens were also present in a patient's circulating T cell repertoire. Analysis of genomic array data from the mesothelioma cohort in The Cancer Genome Atlas suggested that multiple chromothriptic-like events negatively impact survival. CONCLUSIONS: Our findings represent the discovery of potential neoantigen expression driven by structural chromosomal rearrangements. These results may have implications for the development of novel immunotherapeutic strategies and the selection of patients to receive immunotherapies.
INTRODUCTION:Malignant pleural mesothelioma is a disease primarily associated with exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are associated with a high tumor mutation burden, mesothelioma is not. We sought to resolve this discrepancy. METHODS: We used mate-pair (n = 22), RNA (n = 28), and T cell receptor sequencing along with in silico predictions and immunologic assays to understand how structural variants of chromosomes affect the transcriptome. RESULTS: We observed that inter- or intrachromosomal rearrangements were present in every specimen and were frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis. Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones. T cells responsive to these predicted neoantigens were also present in a patient's circulating T cell repertoire. Analysis of genomic array data from the mesothelioma cohort in The Cancer Genome Atlas suggested that multiple chromothriptic-like events negatively impact survival. CONCLUSIONS: Our findings represent the discovery of potential neoantigen expression driven by structural chromosomal rearrangements. These results may have implications for the development of novel immunotherapeutic strategies and the selection of patients to receive immunotherapies.
Authors: Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri Journal: Nat Genet Date: 2016-02-29 Impact factor: 38.330
Authors: Samra Turajlic; Kevin Litchfield; Hang Xu; Rachel Rosenthal; Nicholas McGranahan; James L Reading; Yien Ning S Wong; Andrew Rowan; Nnennaya Kanu; Maise Al Bakir; Tim Chambers; Roberto Salgado; Peter Savas; Sherene Loi; Nicolai J Birkbak; Laurent Sansregret; Martin Gore; James Larkin; Sergio A Quezada; Charles Swanton Journal: Lancet Oncol Date: 2017-07-07 Impact factor: 41.316
Authors: Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman Journal: Blood Date: 2016-06-13 Impact factor: 22.113
Authors: Aaron S Mansfield; Stephen J Murphy; Tobias Peikert; Eunhee S Yi; George Vasmatzis; Dennis A Wigle; Marie Christine Aubry Journal: Clin Cancer Res Date: 2015-12-14 Impact factor: 12.531
Authors: Lauren T Gehman; Peter Stoilov; Jamie Maguire; Andrey Damianov; Chia-Ho Lin; Lily Shiue; Manuel Ares; Istvan Mody; Douglas L Black Journal: Nat Genet Date: 2011-05-29 Impact factor: 38.330
Authors: Jenette Creaney; Shaokang Ma; Sophie A Sneddon; Michelle R Tourigny; Ian M Dick; Justine S Leon; Andrea Khong; Scott A Fisher; Richard A Lake; W Joost Lesterhuis; Anna K Nowak; Shay Leary; Mark W Watson; Bruce W Robinson Journal: Oncoimmunology Date: 2015-05-11 Impact factor: 8.110
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Runzhe Chen; Won-Chul Lee; Anne S Tsao; Jianjun Zhang; Junya Fujimoto; Jun Li; Xin Hu; Reza Mehran; David Rice; Stephen G Swisher; Boris Sepesi; Hai T Tran; Chi-Wan Chow; Latasha D Little; Curtis Gumbs; Cara Haymaker; John V Heymach; Ignacio I Wistuba; J Jack Lee; P Andrew Futreal; Jianhua Zhang; Alexandre Reuben Journal: Clin Cancer Res Date: 2020-08-14 Impact factor: 12.531
Authors: Sounak Gupta; Tatsuo Ito; Deepu Alex; Chad M Vanderbilt; Jason C Chang; Nasrin Islamdoust; Yanming Zhang; Khedoudja Nafa; John Healey; Marc Ladanyi; Meera R Hameed Journal: Hum Pathol Date: 2019-10-25 Impact factor: 3.466